| pubmed-article:16145065 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16145065 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16145065 | lifeskim:mentions | umls-concept:C0023434 | lld:lifeskim |
| pubmed-article:16145065 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:16145065 | lifeskim:mentions | umls-concept:C0059985 | lld:lifeskim |
| pubmed-article:16145065 | lifeskim:mentions | umls-concept:C0383429 | lld:lifeskim |
| pubmed-article:16145065 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:16145065 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:16145065 | lifeskim:mentions | umls-concept:C1704419 | lld:lifeskim |
| pubmed-article:16145065 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:16145065 | pubmed:issue | 28 | lld:pubmed |
| pubmed-article:16145065 | pubmed:dateCreated | 2005-9-29 | lld:pubmed |
| pubmed-article:16145065 | pubmed:abstractText | To determine the efficacy and safety of a newly developed concomitant administration of fludarabine and alemtuzumab (FluCam) in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL). | lld:pubmed |
| pubmed-article:16145065 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16145065 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16145065 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16145065 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16145065 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16145065 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16145065 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16145065 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16145065 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16145065 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16145065 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:16145065 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:JostingAndrea... | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:EngertAndreas... | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:StaibPeterP | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:StützerHartmu... | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:HallekMichael... | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:SchulzHolgerH | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:GramatzkiMart... | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:SchnellRoland... | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:BorchmannPete... | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:TrelleSvenS | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:AulitzkyWalte... | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:ReiserMarcelM | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:ElterThomasT | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:JensenMarkusM | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:SchinkötheTim... | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:RechJürgenJ | lld:pubmed |
| pubmed-article:16145065 | pubmed:author | pubmed-author:HasanIbrahimI | lld:pubmed |
| pubmed-article:16145065 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16145065 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:16145065 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:16145065 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16145065 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16145065 | pubmed:pagination | 7024-31 | lld:pubmed |
| pubmed-article:16145065 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:16145065 | pubmed:meshHeading | pubmed-meshheading:16145065... | lld:pubmed |
| pubmed-article:16145065 | pubmed:meshHeading | pubmed-meshheading:16145065... | lld:pubmed |
| pubmed-article:16145065 | pubmed:meshHeading | pubmed-meshheading:16145065... | lld:pubmed |
| pubmed-article:16145065 | pubmed:meshHeading | pubmed-meshheading:16145065... | lld:pubmed |
| pubmed-article:16145065 | pubmed:meshHeading | pubmed-meshheading:16145065... | lld:pubmed |
| pubmed-article:16145065 | pubmed:meshHeading | pubmed-meshheading:16145065... | lld:pubmed |
| pubmed-article:16145065 | pubmed:meshHeading | pubmed-meshheading:16145065... | lld:pubmed |
| pubmed-article:16145065 | pubmed:meshHeading | pubmed-meshheading:16145065... | lld:pubmed |
| pubmed-article:16145065 | pubmed:meshHeading | pubmed-meshheading:16145065... | lld:pubmed |
| pubmed-article:16145065 | pubmed:meshHeading | pubmed-meshheading:16145065... | lld:pubmed |
| pubmed-article:16145065 | pubmed:meshHeading | pubmed-meshheading:16145065... | lld:pubmed |
| pubmed-article:16145065 | pubmed:meshHeading | pubmed-meshheading:16145065... | lld:pubmed |
| pubmed-article:16145065 | pubmed:meshHeading | pubmed-meshheading:16145065... | lld:pubmed |
| pubmed-article:16145065 | pubmed:meshHeading | pubmed-meshheading:16145065... | lld:pubmed |
| pubmed-article:16145065 | pubmed:meshHeading | pubmed-meshheading:16145065... | lld:pubmed |
| pubmed-article:16145065 | pubmed:meshHeading | pubmed-meshheading:16145065... | lld:pubmed |
| pubmed-article:16145065 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16145065 | pubmed:articleTitle | Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. | lld:pubmed |
| pubmed-article:16145065 | pubmed:affiliation | Department of Hematology and Oncology, University of Cologne, Cologne, Germany. | lld:pubmed |
| pubmed-article:16145065 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16145065 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:16145065 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16145065 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16145065 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16145065 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16145065 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16145065 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16145065 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16145065 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16145065 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16145065 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16145065 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16145065 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16145065 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16145065 | lld:pubmed |
